IRFI 165

Drug Profile

IRFI 165

Latest Information Update: 04 May 2007

Price : $50

At a glance

  • Originator Biomedica Foscama
  • Class Antidepressants; Neuroprotectants; Small molecules
  • Mechanism of Action Adenosine A1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 04 May 2007 Discontinued - Preclinical for Depression in Italy (unspecified route)
  • 20 Oct 2005 Suspended - Preclinical for Depression in Italy (unspecified route)
  • 13 Nov 1997 Preclinical development for Depression in Italy (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top